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Abstract
Background: Metastatic pancreatic adenocarcinoma (PAC) prognosis remains dismal and gemcitabine monotherapy
has been the standard treatment over the last decade. Currently, two first-line regimens are used in this setting:
FOLFIRINOX and nab-paclitaxel plus gemcitabine. Increasing translational data on the predictive value of hENT1 for
determining gemcitabine efficacy suggest that a non-gemcitabine-based regimen is favored in about 60 % of patients
with PAC due to high resistance of PAC to this cytotoxic drug. This study aims to evaluate the efficacy of weekly
nab-paclitaxel combined with gemcitabine or a simplified (s) LV5FU2 regimen in patients with previously untreated
metastatic PAC.
Methods/design: AFUGEM is a two-stage, open-label, randomized, multicenter, phase II trial. Patients with PAC
who meet the inclusion criteria and provide written informed consent will be randomized in a 1:2 ratio to either
nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) given on days 1, 8, and 15 every 28 days or nab-paclitaxel
(125 mg/m2) plus sLV5FU2 (leucovorin 400 mg/m2 followed by bolus 400 mg/m2 5-fluorouracil and by 5-fluorouracil
2400 mg/m2 as an 46-h intravenous infusion) given on days 1 and 15 every 28 days. A total of 114 patients will be
randomized to one of the treatment arms. The primary endpoint is progression-free survival at 4 months. Secondary
outcomes are rate and duration of response, disease control, overall survival, safety, and quality of life. Potential
biomarkers of gemcitabine (hENT1, dCK) and 5-fluorouracil (TS) efficacy will be assessed.
Discussion: The AFUGEM trial is designed to provide valuable information regarding efficacy and tolerability
of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus sLV5FU2 regimens. Identification of potential
predictive biomarkers of gemcitabine and 5-fluorouracil is likely to drive therapeutic decisions in patients
with metastatic PAC.
Trial registration: AFUGEM is registered at Clinicaltrials.gov: NCT01964534, October 15, 2013.
Keywords: Pancreatic adenocarcinoma, Metastatic, Phase II, Nab-paclitaxel, sLV5FU2, hENT1
* Correspondence: jean-baptiste.bachet@psl.aphp.fr
1Paris-Sorbonne University, UPMC University Paris 06, Paris, France
2Department of hepatogastroenterology, Groupe hospitalier Pitié Salpêtrière,
Paris, France
Full list of author information is available at the end of the article
© 2015 Bachet et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bachet et al. BMC Cancer  (2015) 15:653 
DOI 10.1186/s12885-015-1656-4
Background
Pancreatic adenocarcinoma (PAC) is a fatal disease with
poor prognosis and with the incidence increasing regu-
larly in most of the western countries. PAC ranks as the
fourth highest cause of death from cancer [1]. The 5 year
survival is less than 5 % across all stages of disease [2, 3].
At diagnosis, 50–60 % of patients have distant metasta-
ses. In addition, up to 10 % of patients will develop me-
tastases following a curative resection.
Chemotherapy regimens in metastatic PAC
Monotherapy with gemcitabine has been the main thera-
peutic option over the last decade [4]. Several phase III
studies have evaluated this regimen in combinations with
multiple chemotherapy drugs and new targeted therapies.
However, most of these studies were negative and failed to
confer any added overall survival (OS) benefit in compari-
son to gemcitabine alone. Combinations of gemcitabine
with fluoropyrimidine or derivative platinum have only
been associated with a significant OS improvement in
meta-analyses [5–7]. Conroy et al. showed that a
gemcitabine-free triplet combination, FOLFIRINOX (5-
fluorouracil [5FU], irinotecan, and oxaliplatin) achieve
a significant progression-free survival (PFS) and OS
benefit compared to gemcitabine alone in patients with
metastatic PAC in a randomized phase II/III [8]. How-
ever, this trial included only patients with an Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus (PS) of 0–1 and normal total bilirubin level [8].
Nab-paclitaxel is a solvent-free, albumin-bound 130-
nm particle of paclitaxel. Preclinical studies in animals
demonstrated lower toxicities for nab-paclitaxel, with
the maximum-tolerated dose (MTD) approximately
50 % higher for nab-paclitaxel compared to paclitaxel
[9]. At equitoxic doses, treatment with nab-paclitaxel
achieved higher efficacy in an animal model as pro-
vided by paclitaxel dose.
The regimen of nab-paclitaxel plus gemcitabine showed
promising antitumor activity and tolerable toxicity in pa-
tients with metastatic PAC in a phase II trial [10]. In the
following MPACT randomized phase III study, evaluating
the nab-paclitaxel plus gemcitabine vs gemcitabine
monotherapy, median OS (8.5 months vs 6.7 months;
p < 0.0001), median PFS (5.5 months vs 3.7 months;
p < 0.0001) and the response rate (RR; 23 % vs 7 %;
p < 0.0001) were significantly increased in the nab-
paclitaxel plus gemcitabine arm [11]. The safety results
were in concordance with those of the phase II [10]. The
most common grade 3–4 adverse events in the combin-
ation arm and the gemcitabine arm were neutropenia (38
vs 27 %), fatigue (17 vs 7 %), and neuropathy (17 vs 1 %),
respectively [11]. Nab-paclitaxel has subsequently been
approved in the United States and the European Union
for treatment of metastatic PAC.
hENT1 − predictive biomarker of gemcitabine efficacy?
Understanding of the intracellular uptake and metabol-
ism of gemcitabine led to further molecular investigation
of these pathways for potential biomarkers affecting
gemcitabine efficacy. Among biomarkers of potential
clinical utility, the human equilibrative nucleoside trans-
porter 1 (hENT1) has the most promising pre-clinical
and clinical data suggesting its predictive value and thus
value for guiding treatment decisions [12–15]. Gem-
citabine is a hydrophilic prodrug. Its intracellular
diffusion through the plasma membrane is low and
requires specialized integral membrane nucleoside
transporter proteins. Bi-directional hENTs play a key
role in this processs and thus in the efficacy of gem-
citabine [16]. Among these, hENT1 mediates the
majority of gemcitabine transport [17]. Preclinical
studies have suggested a positive correlation between
hENT1 gene expression and gemcitabine chemosen-
sitivity [17].
Data from phase II and phase III studies demonstrated
no predictive value of hENT1 expression [18–20]. These
findings put in question clinical utility of this biomarker.
These studies of gemcitabine in metastatic and adjuvant
setting used the SP120 rabbit monoclonal antibody
[12–14], whereas three studies of adjuvant gemcita-
bine that showed an opposite benefit for hENT1 used
the 10D7G2 monoclonal mouse antibody [18–20].
This difference is likely to be due to a lack of equiva-
lency with a very poor rate of concordance between
these two antibodies [21]. Moreover, a survival benefit
for higher hENT1 expression with the 10D7G2 mouse
antibody vs no benefit with a higher hENT1 expression
with the SP120 rabbit antibody was reported [21].
More studies are necessary to evaluate the best
method for assessing hENT1 expression and to develop
a robust and reproducible scoring system for this bio-
marker. Despite different scoring systems used with the
mouse antibody and its assessment restricted to adjuvant
setting, up to 50–60 % of PACs are resistant to gemcita-
bine due to low or now expression of hENT1 [12–14].
Considering that the predictive value of hENT1 for gem-
citabine efficacy is likely to be confirmed in the near fu-
ture, the nab-paclitaxel plus gemcitabine regimen seems
not to be the best treatment option for patients with low
hENT1 expression.
Rationale to develop the nab-paclitaxel plus sLV5FU2
regimen
For many years, 5FU has been considered as an effi-
cient cytotoxic in PAC. After curative intent resection,
gemcitabine-based and 5FU-based adjuvant chemother-
apy showed similar survival advantage [22]. Moreover,
fluoropyrimidines (capecitabine or 5FU) state key compo-
nents of many first-line (e.g., FOLFIRINOX or gemcitabine
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plus capecitabine) and second-line regimens (e.g., OFF or
5FU plus MM-398) [7, 8, 23–26].
Nab-paclitaxel can be combined with fluoropyrimidine
with tolerable toxicity. The combination of nab-
paclitaxel plus capecitabine is currently being assessed
in an adjuvant randomized phase II/III study in breast
cancer patients at high risk of recurrence (ICE II/GBG
52 trial).
In randomized phase III trials, capecitabine had a bet-
ter toxicity profile compared to 5FU bolus leading to a
significantly lower incidence of grade 3–4 neutropenia
and stomatitis but to an increased incidence of grade 3
hand-foot syndrome [27, 28].
To our knowledge, no randomized studies of capecita-
bine vs LV5FU2 have been reported. Yet, the LV5FU2
regimen was shown to have a better toxicity profile than
5FU bolus with less neutropenia, diarrhea, and stoma-
titis [29]. Therefore, the toxicity profile of the LV5FU2
regimen appears to be closer to the one of capecitabine
than to that of 5FU bolus. In randomized phase III stud-
ies comparing XELOX to FOLFOX4 or FOLFOX6 in pa-
tients with metastatic colorectal cancer, XELOX was
systematically associated with less grade 3–4 neutro-
penia but more grade 3–4 diarrhea and grade 3 hand-
foot syndrome [30–32]. Based on these observations, the
combination of LV5FU2 with nab-paclitaxel may present
treatment option associated with more grade 3–4
neutropenia but probably less diarrhea and hand-foot
syndrome.
In clinical practice, diarrhea is a common side effect in
patients with PAC. In addition, peritoneal carcinoma-
tosis is a common metastatic site in this setting that can
limit oral administration of medication and increase the
risk of digestive toxicity. The hand-foot syndrome is not
easy to manage and requires frequently a dose-reduction
of chemotherapy. Neutropenia represents the major
dose-limiting toxicity, but the use of granulocyte colony
stimulating factor (G-CSF) according to the EORTC
recommendations may help in reducing the rate of
chemotherapy-induced neutropenia and support the use
of dose-intensity chemotherapy [33]. For these reasons,
the LV5FU2 regimen in combination with nab-paclitaxel
will probably be better tolerated than capecitabine.
Translational study
In the past 10 years, an increasing number of transla-
tional studies on potential prognostic and/or predictive
biomarkers in PAC have been published [34, 35]. As
more treatment options are currently available in this
setting, identification of robust biomarkers should be a
priority. This may help in predicting treatment efficacy
and/or in personalizing chemotherapy treatments. Several
predictive biomarkers have been proposed for gemcita-
bine, 5FU, and nab-paclitaxel efficacy.
In addition to hENT1, deoxycitydine kinase (dCK) has
been shown to represent a predictive biomarker of gem-
citabine in patients with PAC. Interestingly, pooled
hENT1 and dCK expression analysis provide supplemen-
tary predictive information as compared to separate ana-
lysis [13].
Numerous mechanisms are involved in the antitumor
effect of 5FU. Among them, the most common is com-
petitive inhibition of thymidylate synthase (TS). Predict-
ive value of TS expression on 5FU sensitivity has been
well described in vitro [36]. In vivo, a large meta-analysis
in colorectal cancer has shown that a high level of TS is
a worse predictive biomarker of OS in metastatic setting
than in adjuvant setting [37]. Thus, TS expression could
be assessed in pancreatic tumors using immunohisto-
chemistry. To our knowledge, no studies have evaluated
the predictive value of TS expression in metastatic PAC.
SPARC is a secreted protein acidic and rich in cysteine
involved in cell matrix. A high expression of SPARC by
peritumoral fibroblasts was described as a negative prog-
nostic biomarker after curative surgery in patients with
PAC [38]. On the contrary, over-expressed SPARC
appeared to correlate with improved OS in patients
treated with the gemcitabine plus nab-paclitaxel regi-
men in the original phase I/II trial of gemcitabine
and nab-paclitaxel, and was suggested as a promising
predictive biomarker of nab-paclitaxel efficacy [10].
The recently reported results from a randomized ad-
juvant study however have shown that a high SPARC
expression is a negative predictive biomarker of adjuvant
gemcitabine benefit [39]. Moreover, neither predictive nor
prognostic value of SPARC expression level (in stromal fi-
broblasts tumoral cells or in plasma) was confirmed in the
phase III MPACT trial [40].
The AFUGEM phase II trial is designed to assess the
tolerability and efficacy of the sLV5FU2 plus nab-
paclitaxel combination in comparison to the new
standard regimen of gemcitabine plus nab-paclitaxel
as first-line treatment in patients with metastatic PAC.
Quality of life assessment and translational research is
performed to determinate the best place and the possibil-
ities of further clinical development of the nab-paclitaxel
plus sLV5FU2 combination. Translational reserach will be
exploratory and no statistical hypothesis plan was made
given that the number of tumor samples available is still
unknown.
Methods/design
Objectives
Primary objective
The primary objective is to assess PFS at 4 months in
both treatment arms: nab-paclitaxel plus gemcitabine
(arm A) and nab-paclitaxel plus simplified LV5FU2 (arm
B). Survival is defined as the time interval between the
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randomization date and the date of either first docu-
mented disease progression (RECIST v1.1) or death of
any cause, whatever occurs first [41]. Patients alive with-
out progression will be censored at the last tumor assess-
ment, either during study treatment period or during
follow-up period.
Secondary objective
The secondary objectives are to evaluate RR (RECIST
v1.1), duration of RR, duration of disease control (DDC),
OS, safety, health-related quality of life (HRQoL), and
the prognostic and predictive value of SPARC, hENT1,
dCK, and TS expression level in both treatment arms
[41]. Survival is defined as the interval between the
randomization date and the date of death from any
cause. Patients still alive at the time of analysis will be
censored at the last date known to be alive, either during
study treatment period or during follow-up period. The
grade of toxicity will be assessed using the NCI-CTC cri-
teria v3.0. Quality of life will be studied by means of the
EORTC QLQ C-30 questionnaire. A deterioration of
scores for five-targeted dimensions: pain, physical and
emotional functioning, fatigue, and appetite will be com-
pared between the two treatment arms, while other di-
mensions will be regarded as exploratory. A 5-point
deterioration in HRQoL scores will be considered as the
minimal clinically important difference (MCID).
Study design
The AFUGEM study is an open-label, randomized, mul-
ticenter phase II trial comparing weekly nab-paclitaxel
with gemcitabine vs nab-paclitaxel with simplified LV5FU2
in patients with previously untreated metastatic PAC
(Table 1 and Fig. 2).
Enrolment
A total of 114 patients will be enrolled in a 1:2 ratio with
38 patients enrolled into the arm A and 76 patients en-
rolled into the arm B.
Stratification
Treatment assignment will be stratified, based on:
i. Center;
ii. ECOG PS 0–1 vs 2
Eligibility criteria
Inclusion criteria
1. Signed and dated informed consent,
2. Patients willing and able to comply with protocol
requirements,
3. Histologically or cytologically proven
adenocarcinoma of the pancreas,
4. Stage IV disease,
5. No prior therapy for metastatic disease (in case of
previous adjuvant therapy, interval between the end
of chemotherapy and relapse must be >12 months),
6. At least one measurable or evaluable lesion as
assessed by CT-scan or MRI according to RECIST
v1.1,
7. Age ≥ 18 years,
8. ECOG PS 0 and 2,
9. Adequate hematologic function: neutrophils > 1.5 x
109/L; platelets > 100 x 109/L; hemoglobin ≥ 9 g/dL,
10.Adequate renal function: serum creatinine level <
150 μM,
11.Adequate liver function: AST (SGOT) and ALT
(SGPT) ≤ 2.5 x ULN (≤5 x ULN in case of liver
metastases), total bilirubin ≤ 1.5 x ULN, albumin ≥
25 g/L,
12.Baseline evaluations performed before
randomization: clinical and blood evaluations no
more than 14 days prior to randomization, tumor
assessment (CT-scan or MRI, evaluation of non-
measurable lesions) no more than 21 days prior to
randomization,
13.Female patients must be surgically sterile, or be
postmenopausal, or must commit to using reliable
and appropriate methods of contraception during
Table 1 Detail of study regimens
Timing of administration Day of administration Drug dose
Arm A
H0 1, 8, 15 nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)
H + 0.5 1, 8, 15 gemcitabine 1000 mg/m2 as a 30-min IV infusion
Arm B
H0 1, 8, 15 nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)
H + 0.5 1, 15 folinic acid 400 mg/m2 (leucovorin, l + d racemic form, or l form 200 mg/m2) in 250 ml glucose 5 %
solution, 2-h IV infusion
H + 2.5 1, 15 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3 1–2, 15–16 5FU continuous infusion 2400 mg/m2, 46-h IV infusion
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the study and during at least 6 months after the end
of study treatment (when applicable). All female
patients with reproductive potential must have a
negative pregnancy test (β HCG) within 72 h prior
to starting nab-paclitaxel treatment. Breastfeeding is
not allowed. Male patients must agree to use effect-
ive contraception in addition to having their partner
use a contraceptive method as well during the trial
and during at least 6 months after the end of the
study treatment,
14.Registration with the French National Health Care
System.
Exclusion criteria
1. Medical history or evidence of CNS metastasis upon
physical examination, unless adequately treated
(e.g., non-irradiated CNS metastasis, seizure not
controlled with standard medical therapy),
2. Local or locally advanced disease (stage I to III),
3. Treatment with warfarin,
4. Uncontrolled hypercalcemia,
5. Pre-existing permanent neuropathy (NCI CTCAE
grade ≥ 2),
6. Known dihydropyrimidine dehydrogenase deficiency,
7. Concomitant unplanned antitumor therapy
(e.g., chemotherapy, molecular targeted therapy,
immunotherapy),
8. Treatment with any other investigational medicinal
product within 28 days prior to study entry,
9. Other serious and uncontrolled non-malignant
disease (e.g., active infection requiring systemic
therapy, coronary stenting or myocardial infarction,
or stroke in the past 6 months),
10. HIV-infected patients or otherwise known to
be HIV-positive with untreated hepatitis B or
hepatitis C,
11. Medical history or active interstitial lung disease,
12. Other concomitant or previous malignancy, except:
i/ adequately treated in-situ carcinoma of the
uterine cervix, ii/ basal or squamous cell carcinoma
of the skin, iii/ cancer in complete remission for >
5 years,
13. Patients with known allergy to any excipient of
study drugs,
14. Concomitant administration of prophylactic
phenytoin and live attenuated virus vaccine such
as yellow fever vaccine.
Randomization
After having properly checked all eligibility criteria,
stratification parameters, and having obtained patient
written consent, patients will be randomized through an
electronic case-report form (eCRF), using a minimization
technique. The minimization algorithm takes into account
the patients already randomized in order to allocate a sub-
sequent treatment. A subgroup of patients who presents
the same stratification variables that the patient to be ran-
domized is isolated. The total number of patient in that
subgroup is counted by stratification variables and by
treatment group. The treatment group that is the less rep-
resented is selected by the system and attributed to the
patient. The randomization result provided by the system
is attributed in 80 % of the cases; otherwise the other
treatment is attributed.
Randomized treatment will be confirmed by e-mail
send to the investigator. All eligible patients must start
study treatment within 7 days of randomization
Ethics
This study is conducted in accordance to the standards
of Good Clinical Practice (ICH-E6), the European
Directive 2001/20/EC, the revised version of the
Declaration of Helsinki, and local regulations. The
protocol has been submitted and approved by the
Agence Nationale de Sécurité du Médicament et des
produits de santé (ANSM; French National Agency
for Medicines and Health Product Safety) and the
Comité de Protection des Personnes – Ile de France
VI (French Ethics Committee).
Written informed consent is obtained from all patients
prior to randomization.
Treatment program
Patients will be treated on an outpatient basis with nab-
paclitaxel plus gemcitabine (Arm A) or nab-paclitaxel
plus sLV5FU2 (Arm B; Fig. 1).
Arm A (Fig. 2; Table 1)
Arm A (nab-paclitaxel plus gemcitabine) consists of
the following regimens: nab-paclitaxel at 125 mg/m2
plus gemcitabine at 1000 mg/m2 both administered as
intravenous (IV) infusion over 30–40 min on days 1, 8,
and 15, followed by 1 week of rest, every 28 days. Treat-
ment continuation is intended until disease progression
or limiting toxicity. If adverse events require dose
interruption of:
– gemcitabine - nab-paclitaxel must be continued until
progression;
– nab-paclitaxel - gemcitabine must be continued until
progression;
– gemcitabine and nab-paclitaxel - a complete break
in therapy is be allowed until disease progression.
Arm B (Fig. 2; Table 1)
Arm B (nab-paclitaxel plus sLV5FU2) consists of the
following regimens: nab-paclitaxel at 125 mg/m2 over
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30–40 min IV infusion on days 1, 8, and 15,
followed by 1 week of rest, every 28 days; folinic
acid 400 mg/m2 (racemic form) or 200 mg/m2 (L-
form) in 250 ml glucose 5 % solution given as a 2 h
IV infusion on days 1 and 15; 5-FU bolus 400 mg/
m2 in 100 ml glucose 5 % solution administered as a
15-min IV infusion on days 1 and 15; and 5-FU
2400 mg/m2 administered as continuous 46-h IV in-
fusion on days 1–2 and 15–16. Treatment adminis-
tration is intended until disease progression or
limiting toxicity.
If adverse events require dose interruption of:
– sLV5FU2 - nab-paclitaxel must be continued until
progression;
– nab-paclitaxel - sLV5FU2 must be continued until
progression;
– sLV5FU2 and nab-paclitaxel - a complete break in
therapy is allowed until disease progression.
In both arms, doses of the first cycle will be adapted
according to ECOG PS at inclusion:
– Patients with ECOG PS 0 or 1 will receive a full
dose at the first cycle,
– Patients with ECOG PS 2 will receive reduced dose by
20 % at the first cycle (nab-paclitaxel 100 mg/m2),
– In absence of toxicity grade 2–4 during the first
cycle, patients with ECOG PS 2 will receive a full
dose at the second cycle.
Fig. 1 Design of study protocol
Fig. 2 Design of study regimens
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A systematic G-CSF prophylaxis is recommended in
both arms according to EORTC recommendations. The
type of G-CSF and treatment duration will be deter-
mined according to local standard of care in each center.
Assessment of tumor response
Tumor response measured using chest-abdominal CT-
scan (or MRI) using RECIST v1.1. For each patient, the
same method of assessment and the same technique
must be used to evaluate each lesion throughout the en-
tire treatment period. If more than one method is used,
the most accurate method according to RECIST v1.1 will
be selected when recording data. Baseline total tumor
burden must be assessed no more than 21 days before
randomization and no more than 28 days before starting
study treatment.
The following items must be available:
At baseline and 14 days follow-up:
– Weight, blood pressure, ECOG PS, neurological
examination, hematology, coagulation, and tumor
markers (CA 19–9 and CEA), radiologic
characteristics (assessed by CT, MRI according to
RECIST v1.1), EORTC QLQ C-30 questionnaire,
– Serum pregnancy test in women of childbearing
potential performed within 72 h prior to nab-
paclitaxel treatment,
– Inclusion and exclusion criteria,
– Paraffin embedded tumor tissue in eligible patients.
During study treatment:
Prior to the schedule dosing (<48 h):
– Concomitant treatment information,
– Weight, blood pressure, ECOG PS, complete and
differential blood counts, hematology, serum
creatinine, total and indirect bilirubin, AST, ALT,
ALP, EORTC QLQ C-30 questionnaire (at day 1 of
every cycle), and toxicity.
Every 2 months:
– Weight, blood pressure, ECOG PS radiological
tumor assessment, complete and differential blood
counts, hematology, albumin plasma, CA 19–9, and
CEA levels, toxicity, and concomitant medication.
If there is a suspicion of disease progression based on
clinical or laboratory findings before the next scheduled
assessment, an unscheduled assessment should be per-
formed. All tumor assessments after baseline will be
done within +/−7 days of the scheduled visit. If the pa-
tient inadvertently misses a prescribed tumor evaluation
or a technical error prevents the evaluation, this patient
may continue treatment until the next assessment and
an unscheduled assessment should be planned as soon
as possible.
End of treatment (28 days after the last dose of any
study drug with a +/− 3 day window):
– Date and reason for end of the study treatment,
– Weight, blood pressure, ECOG PS (Appendix 17.3),
complete and differential blood counts, hematology,
albumin plasma level, EORTC QLQ C-30 question-
naire, toxicity, and concomitant medication.
Follow-up:
– Date of disease progression (if patient is withdrawn
for reasons other than progression),
– Date of initiation and type of any second and
subsequent lines of therapy,
– Date of death.
Statistical analysis
The primary analysis will be performed on modified
intention-to-treat (mITT) population, i.e., all random-
ized patients regardless of their eligibility and received
treatment. Confirmative analyses will be conducted
firstly in the ITT population (patients not assessable and
these who dropped out before month 4 will be consid-
ered as progressive) and in the per protocol (PP) popula-
tion defined as patients who have received at least one
dose of allocated treatment and have no major devia-
tions from the protocol. Analyses of tolerance will be
conducted in all patients who have received at least one
dose of allocated treatment. Unless otherwise indicated
all analyses will present data by treatment arm.
QoL analyses will be conducted in the mITT2 popula-
tion defined as all randomized patients whatever eligibil-
ity criteria were fulfilled and study treatment received
with at least one QoL questionnaire completed at base-
line. The mITT population will be used for the analyses
of all efficacy endpoints.
The following evaluable patient populations are de-
fined for selected endpoints:
– Tumor response will be evaluated in randomized
patients with measurable disease at baseline,
– CA 19–9 response will be evaluated in randomized
patients with available CA 19–9 assessment at
baseline.
Prior to locking the database, a data review meeting
will be planned in order to review individual data and
validate the Statistical Analysis Plan (SAP). All the devia-
tions from protocol definitions (if any) will be listed and
defined as major or minor deviations in the SAP.
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With regard to the safety evaluation, the analysis will
be performed in the total treated set in order to docu-
ment the safety when the treatment is actually received.
Total treated set is defined as all patients who received
at least one administration of assigned treatment. The
safety population will be used for reporting of safety data
and treatment exposure data. Selected efficacy analyses
will be repeated for the ITT population, PP population,
and for subgroups.
Statistical analyses will be performed using eCRF data
collected until a clinical cut-off date that is defined when
the number of events required for the interim and final
analysis of the efficacy variables will be achieved.
Continuous variables will be summarized using de-
scriptive statistics, i.e., number of patients with available
data (N), mean, median, standard deviation (S.D.), 25–
75 % quartile (Q1-Q3), minimum, and maximum. Con-
tinuous variables could be transformed to categorical
variables using the median or using conventional cut-
offs from bibliography or clinical practice. Frequencies
in tables will be presented by arm, total frequency, per-
centages, and missing modality. Qualitative variables will
be summarized by means of counts and percentages.
Unless otherwise stated the calculation of proportions
will based on the sample size of the population of inter-
est. 95 % confidence interval (CI) will be calculated for
the observed 4-month PFS.
Kaplan Meier curves will be used to describe event-
free rates over time. Median event-free times by treat-
ment arm will be reported with 95 % CI, if the number
of events allows the estimation of the median. The confi-
dence interval for the median survival time will be calcu-
lated according to Brookmeyer, R. and Crowley, J.
(1982). Event rates at specified time points will be esti-
mated from the Kaplan-Meier curve and will be reported
with 95 %. The standard error will be estimated by the
Greenwood formula and the log-log transformation will
be used to compute confidence intervals. As exploratory
purpose only, univariate Cox analyses will be done to
compute hazard ratio and its 95 % CI. Follow-up will be
estimated using the reverse Kaplan-Meier method, and
will be described using the median with its 95 % CI.
Clinical and demographic data will be described using
rules form. The statistical parameters mean, median, SD,
and interquartile range and range will be presented for
continuous baseline variables. For categorical baseline
variables, corresponding frequencies (n, %) will be calcu-
lated. All baseline variables listed below will be summa-
rized by treatment arm.
The dose-intensity (DI) of a drug is calculated based on
the number of cycles actually received by the patient. The
relative DI is calculated as the ratio of the DI to the DI in-
dicated in the protocol. The DI indicated in the protocol
is obtained as the dose specified per cycle (mg/m2).
Safety
The following adverse events related to treatment will be
reported:
(i) Any adverse events,
(ii)Any serious adverse events,
(iii)Any serious adverse events related to study
treatment,
(iv)Any NCI-CTC grade 3 or 4 adverse events,
(v) Any adverse events causing discontinuation of study
treatment,
(vi)Any adverse events causing a dose reduction of
study medication,
(vii) Any adverse events leading to death.
Sample size
According to Fleming 2-stage design with a one-sided
5 % type I error and power of 80 %, 72 patients in arm B
(nab-paclitaxel plus sLV5FU2) will need to be random-
ized in order to test the following hypotheses:
 H0 (null): a PFS rate at 4 months of 35 %
(uninteresting to pursue any further investigation),
 H1 (alternative): a PFS rate at 4 months of 50 %
(warrants further investigation in a phase III trial).
The hypotheses regarding an anticipated PFS rate at
4 months of 50 % and an uninteresting rate of 35 % are
based on the observed PFS in metastatic PAC with
ECOG PS 0–2 and treated with first-line gemcitabine
[39, 42].
The control arm will serve as calibration that the pop-
ulations in the two arms are similar: no statistical com-
parison is planned between the two arms.
Stage 1
In arm B, after 4-month follow-up of the first 15 re-
cruited patients:
 if only one patient who is alive is free of progression
at 4 months (6.7 %), the treatment would be
declared uninteresting. No more additional patient
will be included in this arm and the study will be
stopped. Standard treatment (at the investigator’s
discretion) should be given to the potential
progression-free patient.
 if up to 12 patients are alive and free of progression
at 4 months (80 %), 57 additional patients will be
randomized to arm B;
 if 13 or more patients are alive and progression free
at 4 months (86.7 %), the treatment would be
declared a success and deemed worthy of further
phase III study, however an additional 57 patients
will be allocated to arm B.
Bachet et al. BMC Cancer  (2015) 15:653 Page 8 of 11
The probability to conclude for efficacy at the end of
stage 1 is α1 = 0 %, whereas p = 35.0 %.
An early interim analysis is planned for early deter-
mination of the efficacy and safety data.
Stage 2
In arm B, after 4-month follow-up of 72 randomized
patients:
 if 32 or less patients are progression free at
4 months (≤44.4 %), the treatment would be
declared uninteresting,
 if 33 or more patients are progression free at
4 months (≥45.8 %), the treatment would be
regarded as interesting for further evaluation in a
phase III trial.
The probability to conclude for inefficacy at the end of
stage 1 is β2 = 20.4 %, whereas p = 50.0 %. The probabil-
ity to conclude for efficacy at the end of stage 1 is α2 =
3.7 %, whereas p = 35.0 %.
With an expected 5 % drop out/ non-evaluable rate
at 4 months, a total of 114 patients are required (arm
A: N = 38; arm B: N = 76).
Final and specific statistical plan dedicated to QoL
analyses will be written before data frozen.
An analysis will be realized to determine the mechan-
ism of missing data
The method of scoring could take into account the
mechanism of missing data highlighted for example
using multiple imputations taking into account factors
linked to the occurrence of missing data (as a sensitivity
analysis).
A descriptive analysis of the scores obtained for each
questionnaire at baseline and at each follow-up will be
performed using number (N), mean (SD), and median
(range) for all patients and according to the treatment
arm.
The longitudinal analysis of HRQoL will be performed
according to the time to HRQoL score deterioration
(TUDD) approach. The TUDD will be defined as the
time from inclusion in the study to the first deterioration
of a least 5-point MCID of the HRQoL score as com-
pared to the baseline score, with no further improve-
ment as compared to the baseline score.
In sensitivity HRQoL analysis, TUDD defined as
HRQoL deterioration-free survival including all-cause
death as an event, will be explored.
The TUDD will be estimate according to the Kaplan-
Meier estimation method. As exploratory purpose only,
univariate Cox analyses will be done to compute hazard
ratio and its 95 % CI.
As an exploratory univariate and multivariate Cox re-
gression models will be performed in order to estimate
hazard ratio with 95 % CI investigate potential factors
independently associated with the TUDD including time
to progression and time to the first grade 3–4 toxicities.
Translational research project
Paraffin-embedded tumor tissue will be collected prior
to treatment and stored centrally in the tumor bank at
Institute Mutualiste Montsouris, Paris. A systematic
translational research with analysis of immunohisto-
chemistry (blinded with respect to treatment and patient
response) with regard to hENT1, dCK, and TS expres-
sion will be performed using previously reported
methods [13, 37]. Analysis of SPARC expression will be
performed if feasible.
Discussion
After more than 10 years of failure to improve the effi-
cacy of chemotherapy regimens in patients with ad-
vanced PAC, FOLFIRINOX and nab-paclitaxel plus
gemcitabine have emerged as two new treatment stand-
ard based on the results of two phase III trials [8, 11].
However, the indications of FOLFIRINOX are limited to
patients with good PS (ECOG 0–1) and normal bilirubin
level [8]. Given that most patients with metastatic PAC
have a poor PS at diagnosis, FOLFIRINOX is therefore
an option only for a minority of patients. In the MPACT
phase III study, patient selection criteria were less re-
strictive and these with a Karnofsky PS score of 70 or
more were considered eligible [11]. Moreover, prede-
fined sub-groups analysis data suggested that nab-
paclitaxel treatment effect favored patients with negative
prognostic factors (Karnofsky PS, liver metastases, num-
ber of metastatic sites, and level of CA 19–9). The re-
cent results of the CONKO-003 and NAPOLI-1 trials
demonstrated the interest of investigating these regimen
combinations in the second-line setting [25, 26]. Cur-
rently, gemcitabine, fluoropyrimidine, irinotecan, oxalipla-
tin, and nab-paclitaxel are the five available cytotoxic
drugs for treatment of patients with metastatic PAC that
showed anti-tumor efficiency.
Different therapeutic options can be considered to
offer further improvements in the results of PAC treat-
ment. One option will be to increase the number of
drugs used or to optimize the therapeutic sequence.
Such strategies have been evaluated in a phase I study
combining 5FU, oxaliplatin and nab-paclitaxel [43], and
in a phase II trial with sequential administration of gem-
citabine alone followed by FOLFIRI3 regimen during a
2 months alternative period [44]. The promising results
reported in those studies led to the development of nu-
merous trials: e.g., NABPLAGEM (NCT01893801; com-
bination of nab-paclitaxel, cisplatin, and gemcitabine),
GABRINOX (NCT01964287; alternative administration
of nab-paclitaxel plus gemcitabine and FOLFIRINOX),
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and FIRGEMAX (alternative administration of nab-
paclitaxel plus gemcitabine and FOLFIRI3). A major
concern of these strategies will be probably the pro-
file of tolerance that will limit the administration of
these treatments to patients with 0–1 ECOG PS. It
seems necessary therefore to develop more easily tol-
erable combinations for older patients or those with
ECOG PS ≥ 2.
Another option will be to optimize the use of the
available drugs using predictive biomarkers. Such strat-
egy of selecting “the right treatment for the right pa-
tient” will allow to increase the efficacy and to limit the
toxicity. It is of particular interest in metastatic PAC as
most of patients have symptoms and are in PS ≥ 2 at
diagnosis. The AFUGEM trial was designed to optimize
the nab-paclitaxel combination according to predictive
biomarkers. Recent disappointing results on the hENT1
predictive value with the SP120 antibody in patients with
PAC have raised many questions and should be inter-
preted with caution [18–21].
Conclusion
The AFUGEM trial is designed for patients with meta-
static PAC. Two strategies are compared: nab-paclitaxel
plus gemcitabine and nab-paclitaxel plus sLV5FU2 in
order to provide important information on the safety
and efficacy of the nab-paclitaxel plus sLV5FU2 combin-
ation. Parallel translational research will assess the pre-
dictive value of biomarkers of gemcitabine (hENT1,
dCK) and 5FU (TS) efficacy to better determine the best
drug to be added to nab-paclitaxel in individual patients.
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